Acute myeloid leukaemia (in remission) – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acute myeloid leukaemia (in remission) – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-galinpepimut-s-for-patients-with-acute-myeloid-leukemia-in-second-remission/ Wed, 29 Apr 2026 14:58:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-galinpepimut-s-for-patients-with-acute-myeloid-leukemia-in-second-remission/ This clinical trial studies the effectiveness and safety of Galinpepimut-S compared to standard treatment options in patients with Acute Myeloid Leukemia who have achieved a second or later complete remission after salvage therapy. The study uses several medications including Azacitidine, Sargramostim, Cytarabine, Venetoclax, and Decitabine.

The main purpose is to determine if Galinpepimut-S helps patients live longer compared to currently available treatments. The medication is given through injections under the skin, and patients will be monitored regularly to track their response to treatment and any side effects.

The study will evaluate how long patients survive without their disease returning and will also measure the presence of remaining cancer cells in the body. Treatment may continue for up to 36 months, depending on how well patients respond and tolerate the medication.

]]> Study of Venetoclax and Azacitidine for Maintenance Therapy in Patients with Acute Myeloid Leukemia in First Remission After Chemotherapy https://clinicaltrials.eu/trial/study-of-venetoclax-and-azacitidine-for-maintenance-therapy-in-patients-with-acute-myeloid-leukemia-in-first-remission-after-chemotherapy/ Wed, 29 Apr 2026 14:57:15 +0000 https://clinicaltrials.eu/trial/study-of-venetoclax-and-azacitidine-for-maintenance-therapy-in-patients-with-acute-myeloid-leukemia-in-first-remission-after-chemotherapy/ This clinical trial is focused on studying a type of blood cancer called Acute Myeloid Leukemia (AML), specifically in patients who are in their first remission after receiving standard chemotherapy. The study is investigating the use of two medications, Venetoclax and Azacitidine, as maintenance therapy. Maintenance therapy is a treatment given to help keep cancer from coming back after it has gone into remission. Venetoclax, also known by its code name ABT-199, is a medication that comes in the form of a film-coated tablet and is taken orally. Azacitidine is available in tablet form and can also be administered as a powder for suspension for injection, which means it can be given through a vein or under the skin.

The purpose of this study is to determine the best dose of Venetoclax in combination with Azacitidine for patients with AML who have achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after undergoing conventional induction and consolidation chemotherapy. The study will involve different parts, including dose confirmation and dose finding, to establish the recommended dose for these medications when used together as maintenance therapy. Participants will receive the study medications over a period of time, and their health will be monitored to assess the safety and effectiveness of the treatment.

Throughout the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study aims to provide valuable information on how well Venetoclax and Azacitidine work together in maintaining remission in patients with AML, potentially offering a new approach to managing this condition. The trial is expected to continue until 2025, with the goal of improving treatment options for patients with this type of leukemia.

]]> Study on the Effectiveness of Decitabine and Venetoclax for Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-decitabine-and-venetoclax-for-patients-with-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy/ Wed, 29 Apr 2026 14:27:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-decitabine-and-venetoclax-for-patients-with-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy/ This clinical trial is focused on studying a treatment for patients with Acute Myeloid Leukemia (AML) that develops from a group of blood disorders known as myeloproliferative neoplasms. These patients are not suitable for intensive chemotherapy. The study is testing a combination of two medications: decitabine and venetoclax. Decitabine is given as a solution through a vein, while venetoclax is taken as a tablet by mouth.

The purpose of the study is to evaluate how effective this combination treatment is in improving the condition of patients with this type of leukemia. Participants will receive the treatment over a period of time, and their health will be monitored to see how well the treatment works and to check for any side effects. The study will also look at how long patients live without the disease getting worse and how the treatment affects their overall survival.

Throughout the study, researchers will collect information on how patients respond to the treatment, including any changes in their blood counts and overall health. The study aims to provide valuable insights into the potential benefits of using decitabine and venetoclax together for treating this specific type of leukemia. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Study Comparing Clofarabine/Busulfan and Fludarabine/Busulfan for Adults with Acute Myeloid Leukemia Eligible for Stem Cell Transplantation https://clinicaltrials.eu/trial/study-comparing-clofarabine-busulfan-and-fludarabine-busulfan-for-adults-with-acute-myeloid-leukemia-eligible-for-stem-cell-transplantation/ Wed, 29 Apr 2026 14:24:27 +0000 https://clinicaltrials.eu/trial/study-comparing-clofarabine-busulfan-and-fludarabine-busulfan-for-adults-with-acute-myeloid-leukemia-eligible-for-stem-cell-transplantation/ This clinical trial is focused on studying acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. The study aims to compare the effectiveness of two different treatment regimens for patients with AML who are eligible for a type of stem cell transplant called allogeneic stem cell transplantation. The treatments being compared are combinations of medications: one regimen includes clofarabine and busulfan, while the other includes fludarabine and busulfan. These medications are used to prepare the body for the transplant by reducing the intensity of the conditioning process, which is the preparation phase before receiving the stem cells.

The purpose of the study is to compare the survival rates of patients over a two-year period after receiving either of the two treatment regimens. Participants in the study will receive one of the two treatment combinations, and some may receive a placebo. The study will monitor patients’ health and progress over time, assessing various outcomes such as recovery of blood cells, occurrence of any side effects, and overall quality of life. The study will also look at how well the new stem cells are accepted by the body and how the immune system recovers after the transplant.

Throughout the study, patients will undergo regular check-ups and assessments to track their health and response to the treatment. The study will last for several years, with follow-up visits to ensure the safety and effectiveness of the treatments. The ultimate goal is to determine which treatment regimen offers better outcomes for patients with acute myeloid leukemia undergoing stem cell transplantation.

]]>